INCY · Incyte Corp
United States · RS rating 59 · As of 2026-10-14
| Price | 111.57 USD |
|---|---|
| 1-day change | +2.7% |
| RS rating (overall / 1M / 3M / 12M) | 59 / 27 / 45 / 83 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 41 / 49 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -30.8% |
| Sales growth Q/Q | +10.3% |
| Distance from 52-week high | +14.1% |
| Market cap (USD) | $19.0B |